Failure of Dupilimab With Severe Prurigo Nodularis That Responded Well to Abrocitinib

Dermatitis®Ahead of Print LetterFailure of Dupilimab With Severe Prurigo Nodularis That Responded Well to AbrocitinibAshley Vander Does and Gil YosipovitchAshley Vander DoesDr. Phillip Frost Department of Dermatology and Miami Itch Center, University of Miami, Miami, FL, USA.A.V.D. contributed to writing—original draft preparation. G.Y. contributed to conceptualization, writing—reviewing and editing.Search for more papers by this author and Gil YosipovitchDr. Phillip Frost Department of Dermatology and Miami Itch Center, University of Miami, Miami, FL, USA. A.V.D. contributed to writing—original draft preparation. G.Y. contributed to conceptualization, writing—reviewing and editing.Search for more papers by this authorEmail the corresponding author at [email protected]Published Online:27 Feb 2023https://doi.org/10.1089/derm.2022.0065AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Failure of Dupilimab With Severe Prurigo Nodularis That Responded Well to Abrocitinib." Dermatitis, , pp. FiguresReferencesRelatedDetails Volume 0Issue 0 Information© 2023 American Contact Dermatitis Society. All Rights Reserved.To cite this article:Ashley Vander Does and Gil Yosipovitch.Failure of Dupilimab With Severe Prurigo Nodularis That Responded Well to Abrocitinib.Dermatitis®.ahead of printhttp://doi.org/10.1089/derm.2022.0065Online Ahead of Print:February 27, 2023PDF download